Dr. Myron Weisfedlt Joins BioMark’s Scientific Advisory Team

Vancouver, British Columbia – (November 5th, 2018) – BioMark Diagnostics Inc. (“BioMark”) (CSE: BUX, FSE: 20B, OTCQB: BMKDF) is pleased to announce that Dr. Myron Weisfeldt will be joining BioMark’s Scientific Advisory Team.

 

Mr. Rashid Ahmed, CEO and President of BioMark Diagnostics says: “We are extremely proud and honored to have Dr. Myron Weisfeldt join our scientific board. Over the past few months Dr. Weisfeldt provided BioMark with excellent counsel on how to fine tune our lung cancer clinical trial protocols and opened potential new opportunities for collaboration. This is what we at BioMark need as we transition into a fully commercial entity.”

BioMark’s board and shareholders welcome Dr. Weisfeldt and look forward to his professional contribution to building BioMark into a stronger international entity.

 

About Dr. Myron Weisfeldt

 

Dr. Myron Weisfeldt is the Senior Medical Director of Johns Hopkins Technology Ventures. In this position he provides advice on strategies and evaluation of intellectual property of Johns Hopkins to faculty.  He is also University Distinguished Service Professor. From 2001 to 2014 Dr. Weisfeldt was the William Osler Professor of Medicine and Chairman of the Department of Medicine at Johns Hopkins School of Medicine. He was also Physician-in-Chief of the Johns Hopkins Hospital.  Dr. Weisfeldt received a BA and MD from the Johns Hopkins University. He trained in Cardiology at the Massachusetts General Hospital and the National Institutes of Health and from 1975 to 1991, was Director of the Cardiology Division at the Johns Hopkins.  From 1991 to 2001, he was Chairman of the Department of Medicine and Samuel Bard Professor of Medicine at the Columbia University College of Physicians and Surgeons and Director of the Medical Service at the Columbia-Presbyterian Campus of the New York Presbyterian Hospital. Dr. Weisfeldt was Chairman of the Cardiology Advisory Board of the National Heart Lung and Blood Institute from 1987 to 1990 and held the position of President of the American Heart Association in 1990. He is a member of the National Academy of Medicine.

 

His research interests have included heart function, age changes in the heart and circulation, and cardiopulmonary resuscitation. Since 2003 he has been study chair for a large-scale ongoing clinical trials network to conduct randomized definitive trials of devices, drugs and other therapies for out-of-hospital cardiac arrest and severe traumatic injury sponsored by NHLBI and others. This network is called Resuscitation Outcomes Consortium and is now on no cost extension.

Press Release – Dr. Myron Weisfedlt Joins BioMark’s Scientific Advisory Team

BioMark Closes Final Tranche of Private Placement Offering

October 4th, 2018 – Vancouver, British Columbia – BioMark Diagnostics Inc. (“BioMark” or the “Company”) (CSE: BUX) (FSE: 20B) (OTCMKTS: BMKDF) is pleased to announce that further to its press release of September 20, 2017, it has closed the final tranche of a non-brokered private placement for gross proceeds of $222,100.00 wherein BioMark issued 2,221,000 units at a price of $ 0.10 per unit.

 

Each unit consists of one common share of BioMark and one-half of one share purchase warrant. One whole share purchase warrant will entitle the holder thereof to purchase one common share of BioMark at $0.15 per share for a period of two years from the closing date of the private placement, subject to an acceleration clause. No Finders’ fees were payable on the private placement.

 

The proceeds of the private placement will be used for the continuation of the Company’s regulatory submission costs, patent costs, sample acquisition costs and general working capital. The securities issued under the private placement will be subject to a hold period of four months and one day.

 

Certain Insiders, Directors and Officers subscribed for a portion of this placement. Participation of the insiders of the Company in the private placement constitutes a related party transaction as defined under Multilateral Instrument 61-101 (Protection of Minority Security Holders in Special Transactions). Because the Company’s shares trade only on the CSE, the issuance of securities is exempt from the formal valuation requirements of Section 5.4 of MI 61-101 pursuant to Subsection 5.5(b) of MI 61-101 and exempt from the minority approval requirements of Section 5.6 of MI 61-101. The Company did not file a material change report 21 day prior to the closing of the private placement as the details of the participation of insiders of the Company had not been confirmed at that time.

Press Release – Biomark Closes Final Tranche of Private Placement Offering – Oct 4, 2018

Dr. Sandeep Singhal Joins BioMaark Scientific Advisory Team

Vancouver, British Columbia – (October 2nd, 2018) – BioMark Diagnostics Inc. (“BioMark”) (CSE: BUX) (FSE: 20B) (OTCMKTS: BMKDF) is pleased to announce that it has appointed Dr. Sandeep Singhal to its scientific advisory team.

Rashid Ahmed, President and CEO, says, “We are delighted to welcome Dr. Singhal into our scientific advisory team. He provides expertise in clinical trial design, deep analytical data support and integration. His experience is vitally important in validating, improving robustness of our assay(s) and integrating a multi perspective of Omics as a clinical diagnostic tool. His capabilities to develop and implement custom bioinformatics programming solutions in collaboration with labs will be an important asset for BioMark. Dr. Singhal’s contributions will enhance our analytical bench strength as we commence commercialization of our assays which is powered by genomics, metabolomics and big data”.

Leveraging big data from genomics, proteomics and metabolomics (Omics) and incorporating smarter analytics to BioMark’s technology platform will improve the overall performance of the tests significantly. Offering a unified view of these disciplines will lead to better diagnostics tools available to better manage cancer treatment at large says”, Dr. Singhal.

 

About Dr. Sandeep Singhal

Dr. Singhal has over 14 years of experience as a Bioinformatician in India, Belgium, USA and Canada with a strong background in cancer genomics, omic-data integration, modeling, algorithm development, statistical analysis and application implementation. He has published extensively in leading scientific journals such as Nature Genetics, Journal of Clinical Oncology, EMNO molecular medicine. He is an editorial board member of Journal of Current Trends in Translational and Research. Dr Singhal holds Ph.D. in Bioinformatics, from Jules Bordet Institute, Universite libre de Bruxelles (ULB) Bruxelles, Belgium and is currently a Research Scientist at Columbia University, New York where his research focus is to understand the role of metabolism and transcriptional cross talk between epigenetic co-regulators and hormones receptor-mediated signalling pathways in both enhancer function and promoter targeted mechanism of gene control.

Dr. Singhal completed his postdoctoral fellowship at Department of Biomedical Informatics, University of Pittsburgh, & The Hamner Institutes for Health Sciences, North Carolina, USA and University of Alberta Canada.

Press Release – Dr. Sandeep Singhal Joins BioMark Scientific Advisory Team

BioMark Contributes in Scientific Publication

Vancouver, British Columbia – (September 26, 2018) – BioMark Diagnostics Inc. (“BioMark”) (CSE: BUX) (FSE: 20B) (OTCMKTS: BMKDF) is pleased to announce that the article spermidine/spermine N1-acetyltransferase-1 as a diagnostic biomarker in human cancer has been published in the peer-reviewed journal Future Science OA.

 

Rashid Ahmed, President and CEO, says, “We are extremely excited to have worked with a great team of clinicians, scientists and researchers to realize this important publication. It provides confirmation that one of our technology platforms has an important clinical application in the cancer biomarker space. We would like to thank each of the contributing members of the team and express our sincere gratitude to all supporting organizations that made this possible.”

 

“BioMark is looking forward to publishing additional peer reviewed papers in the near term on significant discoveries that it has invested resources over the past few years. BioMark’s technology platform will be appreciated by both clinicians and researchers focused on introducing disruptive technology to help better manage cancer,” says Rashid.

 

The paper is available through open access at https://www.future-science.com/doi/full/10.4155/fsoa-2018-0077. BioMark encourages subscription to Future Science for individuals and institutions interested in keeping abreast of new developments in biotechnology and medicine.

 

About Future Science OA

Future Science and Newlands Press, imprints of Future Science Group, focus on applied science and intellectual property issues in R&D. The journals and eBooks take readers through the pharmaceutical R&D pipeline – from drug discovery, delivery, pharmacokinetics and analytical techniques, through to commentary and analysis on patent and IP issues. The flagship gold open access journal, Future Science OA, also embraces the importance of publishing all good-quality research, and covers all areas of biotechnology and medicine, as well as topics in biological, life and physical sciences that are of relevance to human health.

Future Science Journals

Future Science journals provide research professionals worldwide with a unique source of objective cutting-edge information on the most exciting emerging trends in their field of endeavour.

Access to publications is possible via print and online subscriptions or via pay-per-view purchase via the website (for more information, see Subscriptions and Pricing).

Contact:

Laura Dormer, Editorial Director

Future Science Group,
Unitec House,
2 Albert Place,
London,
N3 1QB, UK

Press Release – BioMark Contributes in Scientific Publication